Predict your next investment

HEALTHCARE | Medical Devices & Equipment
nanoporetech.com

See what CB Insights has to offer

Founded Year

2005

Stage

IPO | IPO

Total Raised

$1.179B

Date of IPO

9/30/2021

About Oxford Nanopore Technologies

Oxford Nanopore Technologies develops a nanopore DNA sequencer, the MinION. The MinION is a portable, real-time, long-read, low-cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.

Oxford Nanopore Technologies Headquarter Location

Oxford, England, OX4 4DQ,

United Kingdom

+44 (0)845 034 7900

Latest Oxford Nanopore Technologies News

Wobble Genomics appoints two high-profile non-executive directors

Oct 21, 2021

Wobble Genomics appoints two high-profile non-executive directors The life sciences company hopes their experience will help grow the firm Sign up to FREE email alerts from businessInsider - DailyInvalid EmailSomething went wrong, please try again later. Subscribe We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info Thank you for subscribingWe have more newsletters Show me See our privacy notice Wobble Genomics has appointed two new non-executive directors to its board as part of its plans to grow and expand the company. The life sciences company, which specialises in RiboNucleic Acid (RNA), appointed Trevor Nicholls and John Leamon to the board. Trevor Nicholls brings 40 years’ experience of building international businesses in the life sciences industry, with a focus on genomics, pharma, and biotech. He worked at McKinsey & Company at the beginning of his career before moving on to a number of senior roles within the life science industry. He worked as a commercial director of the life science business at Amersham International (now Cytiva), chief executive at University of Oxford genomics technology spin-out Oxagen, and chief commercial officer of Affymetrix. He was the chair of Oxford Nanopore Technologies in its early years, with the company raising more than £100m from private and institutional investors during his tenure. Read More US-based John Leamon’s experience is as a scientist and executive with a background in nucleic acid amplification, next generation DNA sequencing, microfluidics, genetics, molecular biology, and product development. He has held positions at 454 Life Sciences, Ion Torrent, Qiagen, and Quantum-Si. Most recently, Leamon has been a SVP of research and development integration at IsoPlexis, advisory board member at Cofactor Genomics, head of strategic partnerships at Homodeus, and head of product development at 4Catalyzer. Richard Kuo, chief executive and founder at Wobble Genomics, said: “Trevor and John are two of the most highly respected individuals in the industry, who bring years of experience and know-how - in terms of running life sciences and biotech businesses, scaling them, product development, global sales, and raising investment from venture capitalists, all things that will be integral to Wobble’s trajectory over the next few months and years.” Earlier this month, Wobble secured a £1.2m investment round led by St Andrews-based investment firm Eos Advisory, alongside the University of Edinburgh’s in-house venture investment fund Old College Capital. Don't miss the latest headlines with our twice-daily newsletter - sign up here for free . Read More

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Oxford Nanopore Technologies

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Oxford Nanopore Technologies in 8 CB Insights research briefs, most recently on Sep 30, 2021.

Expert Collections containing Oxford Nanopore Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford Nanopore Technologies is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

M

Medical Devices

8,112 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

N

Nanobiotechnology

707 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

H

Health Monitoring & Diagnostics

3,092 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

I

Infectious Disease

2,266 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Oxford Nanopore Technologies Patents

Oxford Nanopore Technologies has filed 163 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/31/2019

10/5/2021

Molecular biology, DNA sequencing, Biotechnology, DNA, Analytical chemistry

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/31/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/5/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, DNA sequencing, Biotechnology, DNA, Analytical chemistry

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Oxford Nanopore Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxford Nanopore Technologies Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.